The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury
M. Elias-Miró,
M. B. Jiménez-Castro,
M. Mendes-Braz,
A. Casillas-Ramírez,
C. Peralta
Affiliations
M. Elias-Miró
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Esther Koplowitz Center, Roselló 149–153, 3rd Floor, Office 3.8, 08036 Barcelona, Spain
M. B. Jiménez-Castro
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Esther Koplowitz Center, Roselló 149–153, 3rd Floor, Office 3.8, 08036 Barcelona, Spain
M. Mendes-Braz
Departamento de Patologia e Medicina Legal, Faculdade de Medicina, Universidade de Sao Paulo, 14049-900 Sao Paulo, SP, Brazil
A. Casillas-Ramírez
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Esther Koplowitz Center, Roselló 149–153, 3rd Floor, Office 3.8, 08036 Barcelona, Spain
C. Peralta
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Esther Koplowitz Center, Roselló 149–153, 3rd Floor, Office 3.8, 08036 Barcelona, Spain
Strategies to improve the viability of steatotic livers could reduce the risk of dysfunction after surgery and increase the number of organs suitable for transplantation. Peroxisome proliferator-activated receptors (PPARs) are major regulators of lipid metabolism and inflammation. In this paper, we review the PPAR signaling pathways and present some of their lesser-known functions in liver regeneration. Potential therapies based on PPAR regulation will be discussed. The data suggest that further investigations are required to elucidate whether PPAR could be a potential therapeutic target in liver surgery and to determine the most effective therapies that selectively regulate PPAR with minor side effects.
